XKRX
041960
Market cap608mUSD
Oct 08, Last price
11,360.00KRW
1D
3.27%
1Q
51.47%
Jan 2017
-65.92%
IPO
33.49%
Name
Komipharm International Co Ltd
Chart & performance
P/E
—
P/S
15.56
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.98%
Rev. gr., 5y
7.14%
Revenues
52.47b
-10.74%
Net income
-7.21b
L
CFO
-622m
L
Dividend
Dec 29, 20033.3284 KRW/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Komipharm International Co., Ltd. is a South Korean biopharmaceutical firm specializing in the research, development, and production of veterinary pharmaceuticals and animal vaccines. Their extensive portfolio features vaccines designed for livestock like swine, cattle, and poultry, as well as companion animals such as canines. Complementing these, they offer antibiotics, disinfectants, and bio-fertilizers, in addition to providing clinical laboratory services. The company is also expanding its focus to human health, with ongoing development of anticancer drugs and pain management agents.
Key people
Seong Cheol Moon
President, Co-Chief Executive Officer, Director · since 2007
Yong Jin Yang
Chairman of the Board, Co-Chief Executive Officer · since 2007
Sang Hyeon Kim
Managing Director · since 2013
Yi Geun Park
Internal Auditor
Su Jeong Kim
Director · since 2010
Jeong Gi Yoo
Non-Executive Independent Director · since 2007
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||